Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas. more
Time Frame | FBRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.46% | -2.12% | -2.22% |
1-Month Return | 42.73% | -3.42% | 0.07% |
3-Month Return | 173.16% | -11.13% | 3.71% |
6-Month Return | 54.72% | -5.74% | 8.04% |
1-Year Return | 4.54% | 3.97% | 26.32% |
3-Year Return | -64.51% | 1.05% | 29.42% |
5-Year Return | -90.04% | 34.37% | 83.36% |
10-Year Return | -99.59% | 97.88% | 185.56% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 36.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 11.00K | 54.00K | 36.00K | - | 9.00K | [{"date":"2019-12-31","value":20.37,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":66.67,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":16.67,"profit":true}] |
Gross Profit | (11.00K) | (54.00K) | (36.00K) | - | (9.00K) | [{"date":"2019-12-31","value":-1100000,"profit":false},{"date":"2020-12-31","value":-5400000,"profit":false},{"date":"2021-12-31","value":-3600000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-900000,"profit":false}] |
Gross Margin | (30.56%) | - | - | - | - | [{"date":"2019-12-31","value":-30.56,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.06M | 14.22M | 21.49M | 13.90M | 32.48M | [{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":43.8,"profit":true},{"date":"2021-12-31","value":66.16,"profit":true},{"date":"2022-12-31","value":42.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.06M) | 17.83M | (21.49M) | (13.90M) | (32.49M) | [{"date":"2019-12-31","value":-22.79,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-120.49,"profit":false},{"date":"2022-12-31","value":-77.93,"profit":false},{"date":"2023-12-31","value":-182.18,"profit":false}] |
Total Non-Operating Income/Expense | (1.81K) | - | - | 179.00K | 2.13M | [{"date":"2019-12-31","value":-0.08,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":8.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.07M) | (46.49M) | (21.71M) | (13.88M) | (31.48M) | [{"date":"2019-12-31","value":-406856900,"profit":false},{"date":"2020-12-31","value":-4648700000,"profit":false},{"date":"2021-12-31","value":-2170800000,"profit":false},{"date":"2022-12-31","value":-1387900000,"profit":false},{"date":"2023-12-31","value":-3147600000,"profit":false}] |
Income Taxes | (2.52K) | 32.06M | (200.56K) | (17.00K) | - | [{"date":"2019-12-31","value":-0.01,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.63,"profit":false},{"date":"2022-12-31","value":-0.05,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (4.07M) | - | - | (13.86M) | - | [{"date":"2019-12-31","value":-406604900,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1386200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (4.07M) | (46.49M) | (21.71M) | (13.88M) | (30.48M) | [{"date":"2019-12-31","value":-406856900,"profit":false},{"date":"2020-12-31","value":-4648700000,"profit":false},{"date":"2021-12-31","value":-2170800000,"profit":false},{"date":"2022-12-31","value":-1387900000,"profit":false},{"date":"2023-12-31","value":-3048100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.07M) | (78.54M) | (21.71M) | (13.86M) | (31.48M) | [{"date":"2019-12-31","value":-406604900,"profit":false},{"date":"2020-12-31","value":-7854400000,"profit":false},{"date":"2021-12-31","value":-2170800000,"profit":false},{"date":"2022-12-31","value":-1386200000,"profit":false},{"date":"2023-12-31","value":-3147600000,"profit":false}] |
EPS (Diluted) | (41.10) | (16.79) | (1.54) | (0.79) | (1.10) | [{"date":"2019-12-31","value":-4110,"profit":false},{"date":"2020-12-31","value":-1679,"profit":false},{"date":"2021-12-31","value":-154,"profit":false},{"date":"2022-12-31","value":-79,"profit":false},{"date":"2023-12-31","value":-110.22,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
FBRX | |
---|---|
Cash Ratio | 1.91 |
Current Ratio | 2.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
FBRX | |
---|---|
ROA (LTM) | -81.25% |
ROE (LTM) | -170.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
FBRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.48 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
FBRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 13.35 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.87 |
Forte Biosciences Inc (FBRX) share price today is $18.125
Yes, Indians can buy shares of Forte Biosciences Inc (FBRX) on Vested. To buy Forte Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FBRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Forte Biosciences Inc (FBRX) via the Vested app. You can start investing in Forte Biosciences Inc (FBRX) with a minimum investment of $1.
You can invest in shares of Forte Biosciences Inc (FBRX) via Vested in three simple steps:
The 52-week high price of Forte Biosciences Inc (FBRX) is $28.68. The 52-week low price of Forte Biosciences Inc (FBRX) is $4.11.
The price-to-earnings (P/E) ratio of Forte Biosciences Inc (FBRX) is
The price-to-book (P/B) ratio of Forte Biosciences Inc (FBRX) is 13.35
The dividend yield of Forte Biosciences Inc (FBRX) is 0.00%
The market capitalization of Forte Biosciences Inc (FBRX) is $123.65M
The stock symbol (or ticker) of Forte Biosciences Inc is FBRX